Overview

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Status:
Completed
Trial end date:
2019-03-19
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the efficacy and safety of tolvaptan based on the change in serum sodium concentration following administration of tolvaptan oral tablets at 7.5 to 60 mg/day for up to 30 days in patients with hyponatremia in the SIADH.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Tolvaptan